ONTX Onconova Therapeutics Inc.

1.67
-0.09  -5%
Previous Close 1.76
Open 1.75
Price To Book -2.2
Market Cap 10,017,535
Shares 5,998,524
Volume 270,925
Short Ratio
Av. Daily Volume 140,805

NewsSee all news

  1. Onconova Therapeutics Announces Termination of Proposed Public Offering

    NEWTOWN, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on

  2. Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit

    NEWTOWN, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 Special Protocol Assessment (SPA) submission announced January 2, 2019.
Oral Rigosertib and azacitidine
First-line HR-MDS (high risk myelodysplastic syndromes)
Phase 3 enrolment to be completed 2H 2019. Data anticipated 1H 2020.
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)

Latest News

  1. Onconova Therapeutics Announces Termination of Proposed Public Offering

    NEWTOWN, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on

  2. Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit

    NEWTOWN, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on